Evidence mapPaperPMID 40575340Full record

ArticleWorld journal of gastroenterology2025

Gastroparesis, a diabetic complication causing further, even serious, complications: How to prevent its worsening?

Mauro Bortolotti

Abstract readLetter
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mauro BortolottiDepartment of Internal Medicine and Gastroenterology, S Orsola-Malpighi Polyclinic, University of Bologna (retired), Bologna 40138, Italy. bormau@tin.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastroparesis is a severe diabetic complication, caused by a progressive multifactorial enteric neuropathy. To make an early diagnosis in patients at risk of diabetic gastroparesis is crucial for slow down its progression towards full-blown disease source of further complications and requesting effective, but unsafe, drugs as well as invasive surgical treatments. This aim can be achieved by detecting its first signal represented by the gastric emptying (GE) delay, by using, among the tests to measure GE, the simple, safe, reliable, and easily available one, that is real-time ultrasonography, possibly done annually. Once the GE delay has been identified, it is necessary to evaluate with endoluminal functional lumen imaging probe or manometry whether it depends on pylorospasm, which should be treated by means of non-surgical endoscopic therapies. If, instead, it depends on initial gastropathy, detected by electrogastrograhic body surface gastric mapping, it should be treated with the safest prokinetic drugs and with the newly emerging treatments, thus distancing heavy medical and surgical treatments, while waiting for future solutions.

Indexed as

Diabetes ComplicationsDiabetic NeuropathiesGastroparesisDisease ProgressionEarly DiagnosisGastric EmptyingGastrointestinal AgentsHumansManometryStomachUltrasonographyGastrointestinal AgentsAntiemeticsBody surface gastric mappingDiabetic gastroparesisEndoscopic and surgical treatmentsEnteric neuropathyGastric emptyingGastroparesisNeuromodulatorsProkineticsPylorospasm

Identifiers

PMID40575340
PMCPMC12188790

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.